This Week in Cardiology

Unpublished trials, new CMS rules, statins after cardiac surgery, sudden death in the young, macrolide antibiotics, and FDA Commissioner Dr Robert Califf are discussed this week.

Carotid stenting vs surgery, leadless pacing, the CMS decision on Watchman, pioglitazone after stroke, and subretinal bleeding with antithrombins are discussed by Dr John Mandrola this week.

VA vs Non-VA medical care, flutter ablation in the real world, remote monitoring in heart failure, coffee and ectopy, and influenza and AF are discussed by Dr John Mandrola in this week's podcast.

Controversies over the ROCKET AF trial and Robert Califf's nomination for FDA commissioner, the treatment of ACS, and blood glucose control after cardiac surgery are discussed in this week's podcast.

A draft proposal for data sharing, women and AF, an ICD lead recall, vasovagal syncope, and prediabetes are discussed by Dr John Mandrola in this week's podcast.

AF ablation in persistent AF, complete vs IRA-only revascularization in STEMI, ICDs in women, measuring BP, and a heart-disease moon shot are discussed by Dr John Mandrola in this week's podcast.

Long-QT overdiagnosis and overtreatment, exercise and AF, the athlete's heart, statin eligibility in primary prevention, and cardiac imaging are discussed in this week's podcast.

Risk-based BP treatment, gene variant tests, coronary artery calcium and AF risk, HFpEF therapy, and doctors' decisions are topics discussed by Dr John Mandrola in this week's podcast.

Ezetimibe, bioresorbable stents, guideline adherence, cardiac rehab, ABIM concessions, and end-of-year reviews are covered in this week's podcast.

Mechanical vs bioprosthetic aortic-valve replacement, lack of data for patients with heart and kidney disease, optimism post-ACS, and statin use are discussed by Dr Mandrola in this week's podcast.